Ganetespib

DRUG19 trials

Sponsors

Synta Pharmaceuticals Corp., QuantumLeap Healthcare Collaborative, Cardiff University, Emory University, Dana-Farber Cancer Institute

Conditions

Acute Myeloid LeukaemiaAngiosarcomaBreast CancerBreast NeoplasmsBreast TumorsCancerER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentEarly-stage Breast Cancer

Phase 1

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

CompletedNCT01236144

Cardiff UniversityAcute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome

Start: 2011-04-30End: 2014-01-31Updated: 2014-06-11

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

CompletedNCT01485835

Emory UniversityMultiple Myeloma

Start: 2012-01-31End: 2015-09-30Updated: 2015-10-12

Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma

CompletedNCT01590160

University College, LondonLung Cancer - Malignant Pleural Mesothelioma

Start: 2013-08-31End: 2019-11-05Updated: 2019-11-13

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

TerminatedNCT01962948

Fox Chase Cancer CenterRecurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer

Start: 2013-10-09End: 2018-07-06Updated: 2024-03-26

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

CompletedNCT02008877

Sarcoma Alliance for Research through CollaborationMalignant Peripheral Nerve Sheath Tumors (MPNST), Sarcoma

Start: 2013-12-31End: 2018-07-31Updated: 2019-05-15

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

TerminatedNCT02012192

Medical University InnsbruckEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2014-07-04End: 2017-12-04Updated: 2019-08-13

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

CompletedNCT02060253

Memorial Sloan Kettering Cancer CenterHER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer +4

Start: 2014-04-30End: 2018-06-30Updated: 2018-06-14

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

TerminatedNCT02192541

National Cancer Institute (NCI)Neoplasms

Start: 2014-12-02End: 2016-02-25Updated: 2018-03-29

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

TerminatedNCT02261805

Georgetown UniversityCancer, Small Cell Lung Cancer

Start: 2014-10-31End: 2016-10-31Updated: 2018-04-23

Ganetespib Window of Opportunity Study in Head and Neck Cancers

TerminatedNCT02334319

Emory UniversityStage I Hypopharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma +13

Start: 2014-12-31End: 2016-02-29Updated: 2016-07-26

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

CompletedNCT02389751

M.D. Anderson Cancer CenterGastroesophageal Junction Adenocarcinoma, Malignant Neoplasm of the Cervical Esophagus, Malignant Neoplasm of the Thoracic Esophagus +5

Start: 2015-04-10End: 2019-07-16Updated: 2019-07-24

Phase 2

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

CompletedNCT01039519

Synta Pharmaceuticals Corp.Gastrointestinal Stromal Tumor

Start: 2010-01-31End: 2011-12-31Updated: 2016-03-10

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

RecruitingNCT01042379

QuantumLeap Healthcare CollaborativeAngiosarcoma, Breast Cancer, Breast Neoplasms +8

Start: 2010-03-01End: 2031-12-01Target: 5000Updated: 2026-03-13

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

CompletedNCT01560416

Dana-Farber Cancer InstituteBreast Cancer

Start: 2012-06-01End: 2016-06-26Updated: 2026-03-03

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

CompletedNCT01562015

Synta Pharmaceuticals Corp.Non Small Cell Lung Cancer

Start: 2012-04-30End: 2014-11-30Updated: 2015-05-20

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

CompletedNCT01677455

Synta Pharmaceuticals Corp.Breast Cancer, ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment, HER-2 Positive Breast Cancer +1

Start: 2012-07-31End: 2015-08-31Updated: 2015-11-05

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

CompletedNCT03783949

Universitaire Ziekenhuizen KU LeuvenFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Start: 2018-11-30End: 2023-09-01Updated: 2025-06-11

Phase 3

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

TerminatedNCT01798485

Synta Pharmaceuticals Corp.Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB +1

Start: 2013-04-30End: 2015-12-31Updated: 2016-07-01

Unknown Phase

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

WithdrawnNCT02637375

University of ChicagoBreast Cancer

Start: 2016-05-31End: 2018-12-31Updated: 2016-05-30

Related Papers

Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.

2026-03-25

Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiency

Clinical Cancer Research2026-02-17

Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial

Clinical Cancer Research2026-02-17

Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial

Clinical Cancer Research2026-02-17

Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial

Clinical Cancer Research2026-02-17

CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.

2025-10-24

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial

Frontiers in Oncology2025-07-24

A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images

Physics in Medicine and Biology2025-07-101 citations

Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.

2025-07-012 citations

Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial

Breast Cancer Research2025-06-233 citations

Abstract P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC

Clinical Cancer Research2025-06-13

Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.

Journal of Clinical Oncology2025-05-283 citations

Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).

Journal of Clinical Oncology2025-05-28

I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).

Journal of Clinical Oncology2025-05-28

Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.

Journal of Clinical Oncology2025-05-28

Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO).

2025-05-15

The Confluence of Nanotechnology and Heat Shock Protein 70 in Pioneering Glioblastoma Multiforme Therapy: Forging Pathways Towards Precision Targeting and Transformation.

2025-04-241 citations

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment2024-12-031 citations

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

2024-11-299 citations

Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer.

2024-09-2710 citations

82 more papers not shown